A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma - EMERALD-1

Study identifier:D933GC00001

ClinicalTrials.gov identifier:NCT03778957

EudraCT identifier:2018-002134-20

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1)

Medical condition

Hepatocellular Carcinoma

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab, Bevacizumab

Sex

All

Actual Enrollment

724

Study type

Interventional

Age

18 Years - 110 Years

Date

Study Start Date: 30 Nov 2018
Primary Completion Date: 11 Sept 2023
Estimated Study Completion Date: 31 Aug 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria